AstraZeneca’s Lokelma Approved In US With Label Benefits Over Veltassa
Executive Summary
After delays caused by two complete response letters, AstraZeneca’s Lokelma has been approved in the US with label benefits over its major competitor, Vifor Pharma’s Veltassa.